| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Rapport Therapeutics, Inc. (RAPP) has 13 insiders with recent SEC Form 4 filings, including 0 buys and 22 sells. RAPP is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 6.71M | $255.49M | -426,005 | |
| CEO | 571.3K | $21.76M | - | |
| Other | 395.8K | $15.07M | - | |
| Other | 297.0K | $11.31M | - | |
| COO | 171.9K | $6.55M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 17, 2026 | Third Rock Ventures V, L.P. | 10% Owner | Sell | 426,005 | $40.32 | $17,175,243.59 | -6.0% | - | - | |
| Jan 15, 2026 | Bredt David | Chief Scientific Officer | Sell | 8,500 | $26.84 | $228,131.65 | -1.1% | +27.2% | - | |
| Dec 31, 2025 | Bredt David | Chief Scientific Officer | Sell | 6,567 | $30.05 | $197,337.69 | -1.6% | +3.1% | - | |
| Dec 31, 2025 | Yeleswaram Krishnaswamy | Chief Development Officer | Sell | 2,840 | $30.05 | $85,342.00 | -0.9% | +3.1% | - | |
| Dec 17, 2025 | Ceesay Abraham | Chief Executive Officer | Sell | 10,916 | $29.64 | $323,508.33 | -0.6% | -3.3% | - | |
| Dec 15, 2025 | Bredt David | Chief Scientific Officer | Sell | 8,500 | $30.02 | $255,129.97 | -1.1% | -6.7% | - | |
| Nov 26, 2025 | Gault Cheryl | Chief Operating Officer | Sale+OE | 5,000 | $30.10 | $150,486.50 | -2.8% | -1.5% | - | |
| Nov 17, 2025 | Ceesay Abraham | Chief Executive Officer | Sell | 10,916 | $25.20 | $275,046.92 | -0.9% | +15.7% | - | |
| Nov 17, 2025 | Bredt David | Chief Scientific Officer | Sell | 8,500 | $25.19 | $214,090.64 | -1.0% | +15.7% | - | |
| Oct 15, 2025 | Bredt David | Chief Scientific Officer | Sell | 8,500 | $25.79 | $219,196.21 | -1.0% | +5.1% | - |